lenabasum

Small moleculeexperimental

Clinical trial activity

3 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
2
Phase 4
0

Earliest trial started Dec 18, 2017 (NCT03398837)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetUnclear

    unclear

Chemistry & pharmacology

Loading structure…

SMILES

CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CC=C(C(=O)O)C[C@@H]21
Mol. weight
400.56 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03813160Phase 3Dec 17, 2018Corbus Pharmaceuticals Inc., University of Pennsylvania, University of Pittsburgh
NCT03451045Phase 2Dec 22, 2017Corbus Pharmaceuticals Inc., Cystic Fibrosis Foundation Therapeutics, Imperial College London, Rainbow Baby and Children's Hospital
NCT03398837Phase 3Dec 18, 2017Corbus Pharmaceuticals Inc., Cornell University, University of London
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Corbus Pharmaceuticals Inc.For profit3322017
Cornell UniversityAcademic/Hospital1012017
Cystic Fibrosis Foundation TherapeuticsAcademic/Hospital1012017
Imperial College LondonAcademic/Hospital1012017
Rainbow Baby and Children's HospitalAcademic/Hospital1012017
University of LondonAcademic/Hospital1012017
University of PennsylvaniaAcademic/Hospital1012018
University of PittsburghAcademic/Hospital1012018
8 organizations
Page 1 / 1